Tempus AI, Inc. (NASDAQ: TEM) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $11.5B. The Maz Rating grades it against the other companies in its sector.
Tempus AI, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $64.76, Tempus AI, Inc. trades at 7.6x sales and 23.5x book value. Over the last twelve months it generated about $1.5B of revenue and a net loss of $186M. It runs a gross margin of 64.5%, an operating margin of -18.5% and a net margin of -12.5%. It shows return on equity of -40.9%, return on invested capital of -13.4% and a free cash flow yield of -1.3%. On the balance sheet: a debt-to-equity ratio of 2.86 and a current ratio of 2.61. Over the past 52 weeks the share price ranged from $40.77 to $89.09, with a beta of 3.61.
Tempus AI, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 11 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Tempus AI, Inc. (TEM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 10.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.41% / 30% · Interest income / Revenue 0.97% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 10.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.00% / 33% · Receivables / Mkt Cap (36m) 2.99% / 49% · Interest income / Revenue 0.97% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 10.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.00% / 33.33% · Receivables / Mkt Cap (24m) 2.99% / 33.33% · Interest income / Revenue 0.97% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 56.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 30.9% / 33.33% · Receivables / Avg Assets (4Q) 15.2% / 33.33% · Interest income / Revenue 0.97% / 5% | Fail |
| FTSE | Debt / Total Assets 55.1% / 33.33% · (Cash+ST Inv) / Total Assets 26.0% / 33.33% · (Cash+Recv) / Total Assets 41.5% / 33.33% · Interest income / Revenue 0.97% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Tempus AI, Inc. (TEM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Tempus AI, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.97% of each dividend: Tempus AI, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.